FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913378748> ?p ?o ?g. }

• W2913378748 endingPage "3144" @default.
• W2913378748 startingPage "3144" @default.
• W2913378748 abstract "Abstract BACKGROUND The prior Australasian Leukaemia and Lymphoma Group (ALLG) CLL5 Study showed dose-reduced oral fludarabine and cyclophosphamide plus rituximab (FCR3) was safe, tolerable and effective in fit elderly patients for front-line therapy for CLL. The German CLL11 Study showed chlorambucil plus obinutuzumab (Cbl+G) was superior to chlorambucil alone or with rituximab in unfit patients requiring initial therapy. We conducted a randomized study to assess the safety, tolerability, and efficacy of dose-reduced FC + obinutuzumab (G) (FC+G) versus Cbl+G in unfit (i.e. with comorbidity), elderly patients with CLL. METHODS Patients aged ≥65 years and considered unfit defined by co-morbidities using the Cumulative Illness Rating Scale [CIRS] ≥6 were eligible for the ALLG CLL7 study. Patients with any single organ system score ≥4 were excluded. Previously untreated patients with progressive CLL aged ≥65 and CIRS ≥6 were randomised to one of 2 therapy arms: (i) Chlorambucil 0.5mg/kg D1+15 p.o. + obinutuzumab (G) (i.v. 1000mg/m2 cycle 1, Day 1, 8, 15, and 1000mg/m2 D1 cycles 2-6), or (ii) FC(rd)+G: F-24mg/m2 p.o. and C-150mg/m2 p.o. D1-3 + G (same schedule above) at 4 weekly intervals for planned 6 cycles. Early stopping for toxicity was mandated: treatment could be delayed for 2 weeks for grade 3+ toxicity, but if unresolved by 2 weeks, patients were taken off study. The primary end-point was grade 3+ non-hematological, and grade 4 hematological adverse events. Secondary objectives were overall response rate (ORR), complete remission (CR), partial remission (PR), progression-free survival (PFS) and overall survival (OS) and minimal residual disease (MRD) negativity. Final staging was performed between 2-3 months following final treatment cycle. RESULTS Patient characteristics Patient recruitment was terminated early due to poor recruitment. At the time of study closure, there were 32 patients, with 15 on Cbl+G and 17 on FC(rd)+G. The mean age was 74.2 years (range 66-85 years) with 23 females (71.9%) and 9 males (28.1%). The CIRS score was 6 in 4 patients (12.5%), 6-8 in 14 (43.8%), 8-10 in 11 (34.4%) and >10 in 3 (9.4%). Binet stage at registration was stage A 18.2%, B 27.3% and C 54.5%. Tolerability Both therapies were tolerable with 15/17 (88.2%) completing all 6 cycles of FC(rd)+G and 12/15 (92.3%) completing six cycles of Cbl+G. Toxicity Most toxicity was hematological and manageable. Grade 3/4 hematological toxicity was more common with FC(rd)+G than Cbl+G occurring in 60% with FC(rd)+G and 38.5% with Cbl+G (Table 1). There was one death due to progressive CLL on the FC(rd)+G arm. Response rate A complete remission (CR), confirmed by bone marrow (BM) trephine, was achieved in 86.6% of patients on FC(rd)+G versus (vs) 53.9% on Cbl+G, partial response (PR/nPR) in 1 (6.7%) on FC(rd)+G, and 6 (46.2%) on Cbl+G, and either stable or progressive disease (SD or PD) on 1 on FC(rd)+G, and nil on Cbl+G. BM MRD-negativity rates were 3/17 (20.0%) FC(rd)+G vs 1/15 (7.7%) Cbl+G (Table 2). CONCLUSION This randomized trial of dose-reduced FC(rd)+G vs Cbl+G in elderly patients aged ≥65 and with co-morbidities (CIRS ≥6) was terminated early due to poor recruitment. Due to the dose-reduced FC, and early stopping rule, treatment was safe and tolerable and most patients completed all 6 cycles of planned therapy. Grade 3/4 toxicity was mainly hematological and manageable, with higher rates of neutropenia with the FC (60%) vs Cbl (35.7%) backbone. FC(rd)+G compared to Cbl+G resulted a higher CR rate of 86.6%% versus 53.9%, and higher MRD-negativity (20% vs 7.7%). Progression-free and overall survival are being evaluated. Disclosures Badoux: Roche: Research Funding. Cull:Takeda Australia: Other: Travel Expenses; Amgen Australia: Other: Travel Expenses; AbbVie (Australia): Membership on an entity's Board of Directors or advisory committees. Tam:Janssen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Pharmacyclics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BeiGene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding." @default.
• W2913378748 created "2019-02-21" @default.
• W2913378748 creator A5001949103 @default.
• W2913378748 creator A5002467749 @default.
• W2913378748 creator A5012712238 @default.
• W2913378748 creator A5034517642 @default.
• W2913378748 creator A5044744306 @default.
• W2913378748 creator A5044831223 @default.
• W2913378748 creator A5045202945 @default.
• W2913378748 creator A5067388673 @default.
• W2913378748 creator A5078917644 @default.
• W2913378748 creator A5085393928 @default.
• W2913378748 creator A5087985272 @default.
• W2913378748 creator A5090116607 @default.
• W2913378748 date "2018-11-29" @default.
• W2913378748 modified "2023-09-27" @default.
• W2913378748 title "Randomized Trial in Unfit, Elderly Chronic Lymphocytic Leukemia (CLL) Patients with Comorbidities of Dose-Reduced Oral Fludarabine and Cyclophosphamide Plus Obinutuzumab (FC+G) Versus Chlorambucil Plus Obinutuzumab (Cbl+G) As Front-Line Therapy" @default.
• W2913378748 doi "https://doi.org/10.1182/blood-2018-99-116287" @default.
• W2913378748 hasPublicationYear "2018" @default.
• W2913378748 type Work @default.
• W2913378748 sameAs 2913378748 @default.
• W2913378748 citedByCount "0" @default.
• W2913378748 crossrefType "journal-article" @default.
• W2913378748 hasAuthorship W2913378748A5001949103 @default.
• W2913378748 hasAuthorship W2913378748A5002467749 @default.
• W2913378748 hasAuthorship W2913378748A5012712238 @default.
• W2913378748 hasAuthorship W2913378748A5034517642 @default.
• W2913378748 hasAuthorship W2913378748A5044744306 @default.
• W2913378748 hasAuthorship W2913378748A5044831223 @default.
• W2913378748 hasAuthorship W2913378748A5045202945 @default.
• W2913378748 hasAuthorship W2913378748A5067388673 @default.
• W2913378748 hasAuthorship W2913378748A5078917644 @default.
• W2913378748 hasAuthorship W2913378748A5085393928 @default.
• W2913378748 hasAuthorship W2913378748A5087985272 @default.
• W2913378748 hasAuthorship W2913378748A5090116607 @default.
• W2913378748 hasConcept C126322002 @default.
• W2913378748 hasConcept C141071460 @default.
• W2913378748 hasConcept C143998085 @default.
• W2913378748 hasConcept C197934379 @default.
• W2913378748 hasConcept C2776694085 @default.
• W2913378748 hasConcept C2776755627 @default.
• W2913378748 hasConcept C2777607594 @default.
• W2913378748 hasConcept C2777866208 @default.
• W2913378748 hasConcept C2777938653 @default.
• W2913378748 hasConcept C2778375690 @default.
• W2913378748 hasConcept C2778461978 @default.
• W2913378748 hasConcept C2779263901 @default.
• W2913378748 hasConcept C2779338263 @default.
• W2913378748 hasConcept C2780653079 @default.
• W2913378748 hasConcept C71924100 @default.
• W2913378748 hasConcept C90924648 @default.
• W2913378748 hasConceptScore W2913378748C126322002 @default.
• W2913378748 hasConceptScore W2913378748C141071460 @default.
• W2913378748 hasConceptScore W2913378748C143998085 @default.
• W2913378748 hasConceptScore W2913378748C197934379 @default.
• W2913378748 hasConceptScore W2913378748C2776694085 @default.
• W2913378748 hasConceptScore W2913378748C2776755627 @default.
• W2913378748 hasConceptScore W2913378748C2777607594 @default.
• W2913378748 hasConceptScore W2913378748C2777866208 @default.
• W2913378748 hasConceptScore W2913378748C2777938653 @default.
• W2913378748 hasConceptScore W2913378748C2778375690 @default.
• W2913378748 hasConceptScore W2913378748C2778461978 @default.
• W2913378748 hasConceptScore W2913378748C2779263901 @default.
• W2913378748 hasConceptScore W2913378748C2779338263 @default.
• W2913378748 hasConceptScore W2913378748C2780653079 @default.
• W2913378748 hasConceptScore W2913378748C71924100 @default.
• W2913378748 hasConceptScore W2913378748C90924648 @default.
• W2913378748 hasIssue "Supplement 1" @default.
• W2913378748 hasLocation W29133787481 @default.
• W2913378748 hasOpenAccess W2913378748 @default.
• W2913378748 hasPrimaryLocation W29133787481 @default.
• W2913378748 hasRelatedWork W1796006501 @default.
• W2913378748 hasRelatedWork W203548035 @default.
• W2913378748 hasRelatedWork W2173371792 @default.
• W2913378748 hasRelatedWork W2606155555 @default.
• W2913378748 hasRelatedWork W2725087275 @default.
• W2913378748 hasRelatedWork W2900648479 @default.
• W2913378748 hasRelatedWork W2902300122 @default.
• W2913378748 hasRelatedWork W3015876203 @default.
• W2913378748 hasRelatedWork W2183070500 @default.
• W2913378748 hasRelatedWork W2912615048 @default.
• W2913378748 hasVolume "132" @default.
• W2913378748 isParatext "false" @default.
• W2913378748 isRetracted "false" @default.
• W2913378748 magId "2913378748" @default.
• W2913378748 workType "article" @default.